Form 4: ALX Oncology Interim CFO, Shelly Pinto, Acquires 150,000 Stock Options

Shelly Pinto, Interim CFO of ALX Oncology Holdings Inc., was granted 150,000 stock options on December 2, 2024, according to a recent SEC filing.

Summary

• Shelly Pinto, the Interim CFO of ALX Oncology Holdings Inc., has been granted 150,000 stock options.
• The options were granted on December 2, 2024, with an exercise price of $1.66 per share.
• The options vest in 30 equal monthly installments starting on January 2, 2025.
• A power of attorney was also executed on December 3, 2024, authorizing Jason Lettmann and Chris Byrd to file SEC forms on behalf of Shelly Pinto.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options to the Interim CFO aligns her interests with the company's performance.
• The vesting schedule encourages long-term commitment from the Interim CFO.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech sector where stock options are a common form of compensation.

Comparison to Industry Standards

• Stock option grants are a common practice in the biotechnology industry to align executive interests with shareholder value.
• The vesting schedule of 30 months is fairly standard for executive stock options.
• The exercise price of $1.66 is typical for options granted at the current market price or a slight premium.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the Interim CFO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, SEC Form 4, insider trading, executive compensation, ALX Oncology, Shelly Pinto, power of attorney